Zafgen Inc (ZFGN) reported quarterly earnings results on Tuesday, May-10-2016. The company said it had a profit of $-0.65 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.07. Analysts had a consensus of $-0.72. During the same quarter in the previous year, the company posted $-0.53 EPS.
Many Wall Street Analysts have commented on Zafgen Inc. Shares were Reiterated by RBC Capital Mkts on Mar 10, 2016 to “Outperform” and Lowered the Price Target to $ 19 from a previous price target of $21 .
Zafgen Inc opened for trading at $5.91 and hit $6.23 on the upside on Friday, eventually ending the session at $6.13, with a gain of 2.85% or 0.17 points. The heightened volatility saw the trading volume jump to 3,64,246 shares. Company has a market cap of $167 M.
In a different news, on Oct 20, 2015, Dennis D Kim (Chief Medical Officer) sold 39,407 shares at $40.00 per share price. According to the SEC, on Sep 25, 2015, Kevin P Starr (director) sold 136,579 shares at $43.92 per share price. On Sep 22, 2015, Alicia Secor (Chief Commercial Officer) sold 26,256 shares at $41.05 per share price, according to the Form-4 filing with the securities and exchange commission.
Zafgen Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications including severe obesity in two rare diseases Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO) including craniopharyngioma-associated obesity and severe obesity. Beloranib is in Phase III stage of development for obesity and hyperphagia in patients with PWS; completed Phase II clinical trial for HIAO and is in Phase IIb stage of development for severe obesity in the general population. The Company’s other product candidate ZGN-839 is in pre-clinical development stage. The Company is also evaluating the additional MetAP2 inhibitors beyond Beloranib as potential development candidates for the treatment of severe obesity.